The binding of HIV-1 protease inhibitors to human serum proteins

Biophysical Chemistry

Volumn 105, Issue 2-3, 2003, Pages 221-230

  Schön, Arne ^a   Del Mar Ingaramo, Maria ^a   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AIDS; Calorimetry; HIV 1 protease; Human serum albumin; Protease inhibitor; 1 acid glycoprotein

Indexed keywords

INDINAVIR; KNI 764; NELFINAVIR; OROSOMUCOID; PLASMA PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEINASE INHIBITION; THERMODYNAMICS; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0141672041     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-4622(03)00071-1     Document Type: Article

References (27)

1. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
2. Williams G.C., Sinko P.J. Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Del. Rev. 39:1999;211-238.
3. Peters T. Jr. All about Albumin: Biochemistry, Genetics and Biomedical Applications. 1996;Academic Press, San Diego.
4. Israili Z.H., Dayton P.G. Human alpha-1-glycoprotein and its interaction with drugs. Drug Metab. Rev. 33:2001;161-235.
5. Kremer J.M.H., Wilting J., Jansen L.H.M. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40:1988;1-47.
6. Velazquez-Campoy A., Kiso Y., Freire E. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390:2001;169-175.
7. Patrito L.C., Martin A. Isolation and purification of alpha-1-acid glycoprotein from human liver. Hoppe-Seyler's Z. Physiol. Chem. 352:1971;89-96.
8. Pace C.N., Vajdos F., Fee L., Grimsley G., Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4:1995;2411-2423.
9. Muzammil S., Kumar Y., Tayyab S. Anion-induced refolding of human serum albumin under low pH conditions. Biochim. Biophys. Acta. 1476:2000;139-148.
10. Todd M.J., Luque I., Velazquez-Campoy A., Freire E. The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry. 39:2000;11876-11883.
11. Todd M.J., Semo N., Freire E. The structural stability of the HIV-1 protease. J. Mol. Biol. 283:1998;475-488.
12. Todd M.J., Freire E. The effect on inhibitor binding on the structural stability and cooperativity of the HIV-1 protease. Proteins. 36:1999;147-156.
13. 1-acid glycoprotein. Br. J. Clin. Pharmacol. 36:1993;241-249.
14. 1-acid glycoprotein. Pharmacogenetics. 6:1996;403-415.
15. 1-acid glycoprotein. J. Pharm. Sci. 89:2000;751-757.
16. Velazquez-Campoy A., Todd M.J., Vega S., Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc. Natl. Acad. Sci. USA. 98:2001;6062-6067.
17. 1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. Br. J. Clin. Pharmacol. 51:2001;99-102.
18. + cell counts, and HIV-1 production by cells. Science. 271:1996;670-672.
19. Furman P.A., Fyfe J.A., Clair M.H.St., Weinhold K., Rideout J.L., Freeman G.A., et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 83:1986;8333-8337.
20. Coffin J.M., Hughes S.H., Varmus H.E. Retroviruses. 1997;Cold Spring Harbor Laboratory Press.
21. Molla A., Vasavanonda S., Kumar G., Sham H.L., Johnson M., Grabowski B., et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology. 250:1998;255-262.
22. Markowitz M., Mo H., Kempf D.J., Norbeck D.W., Bhat T.N., Erickson J.W., et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:1995;701-706.
23. Klabe R.M., Bacheler L.T., Ala P.J., Erickson-Viitanen S., Meek J.L. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry. 37:1998;8735-8742.
24. Ala P.J., Huston E.E., Klabe R.M., Jadhav P.K., Lam P.Y.S., Chang C.-H. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry. 37:1998;15042-15049.
25. Durant J., Clevenbergh P., Garraffo R., Halfon P., Icard S., Del Giudice P., et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS. 14:2000;1333-1339.
26. Luque I., Freire E. Structure-based prediction of binding affinities and molecular design of peptide ligands. Methods Enzymol. 295:1998;100-127.
27. Luque I., Freire E. Structural parameterization of the binding enthalpy of small ligands. Proteins. 49:2002;181-190.